? Standard Press Release Format & Layout Guide

If you're writing a professional press release, formatting matters just as much as the content. Journalists expect a clean, traditional layout that is easy to scan and structured properly.

Below is the standard press release format used by most media outlets.

California: Supreme Court Rules Police Can’t Search Vehicles Based on “Weed Crumbs”
by NORML Posted on February 5, 2026

Sacramento, CA: Police may neither charge a motorist with violating California’s “open container law” nor search a person’s vehicle solely upon the identification of a small quantity of marijuana “crumbs” on the floorboards, according to a ruling handed down by the state’s Supreme Court.

In a unanimous opinion, the Justices determined that the state’s “open container” law should not be applied so broadly as to pertain to situations where police find “any loose marijuana” in a motor vehicle. Rather, the court decided that the marijuana “must be of a usable quantity, in imminently usable condition, and readily accessible to an occupant” to constitute a violation of the state’s “open container” law.

The Court further determined that a police officer’s identification of “weed crumbs” does not provide probable cause for a warrantless vehicle search. They ruled, “The marijuana-related conduct here – possession of the rolling tray on the backseat and the crumbs on the floor [totaling 0.36 grams] – was lawful and alone was insufficient to find probable cause of a violation of California’s controlled substances law.”

The Supreme Court’s ruling reverses the decision of the California Court of Appeals, which had previously granted police the authority to search the defendant’s vehicle based upon a finding of probable cause.

The case is Sellers v. The Superior Court of Sacramento County.

https://norml.org/news/2026/02/05/califo...ed-crumbs/

The Cannabist Company and Ric Flair Drip Launch Partnership in Delaware
Signature Cannabis Line from Wrestling Icon Ric Flair to Expand Into Additional Markets in 2025
December 19, 2024

Cannabis Finally Gets Its Own AI
New York, New York (Newsworthy.ai) Tuesday Jul 29, 2025 @ 7:00 AM UTC

Newton Insights has released the first cannabis-trained AI model, built on 400+ peer-reviewed studies and 160,000 expert Q&As. With 83.6% accuracy on science benchmarks, it helps extraction teams reduce trial-and-error and make real-time, evidence-based decisions grounded in validated research.

Newton Insights' new AI model offers cannabis operators a competitive edge by providing science-backed answers to optimize extraction and formulation processes.
Newton Insights' AI model advances the cannabis industry by reducing waste and improving efficiency, contributing to a more sustainable and scientifically informed future.
The AI model by Newton Insights is built on 400+ peer-reviewed studies, generating 160,000 expert-level Q&As for precise cannabis extraction and formulation guidance.
Discover how Newton Insights' cannabis-specific AI, outperforming GPT-4 and Claude 3, revolutionizes extraction with 160,000 expert-level Q&As from 400+ studies.

For the first time, cannabis operators no longer have to choose between handcrafted experience and disconnected academic theory. Newton Insights today released the most advanced cannabis-specific AI model ever developed — a domain-trained LLM built on 400+ peer-reviewed studies that generated 160,000 expert-level Q&As. The result: instant, science-backed answers to the toughest extraction and formulation questions, all tailored to the realities of real-world operations.

Quote:"This LLM changes that equation completely, We're giving extraction teams the scientific foundation they need to optimize their processes without the guesswork."- Co-Founder Kellan Finney

Quote:"Cannabis teams are drowning in data but starving for clarity," said Bryan Fields, Co-Founder of Newton Insights. "The industry has been stuck choosing between academic theory and trial-and-error experience."

Quote:"This LLM changes that equation completely," adds Co-Founder Kellan Finney. "We're giving extraction teams the scientific foundation they need to optimize their processes without the guesswork."

• 161,170 expert-level Q&As covering cannabis chemistry, biology, and extraction
  
• 83.6% accuracy on scientific benchmarks — outperforming GPT-4 (60.2%) and Claude 3 (66.7%) on cannabis-specific tasks
  
• Trained for depth, not breadth — a domain expert purpose-built for cannabis operations
  
• Built from 400+ peer-reviewed studies and 127M+ science tokens
  
• Outperforms other 8B-class models in science Q&A by 10–20 points — despite a smaller size and tighter domain scope
  
• Real-World Applications for Extraction Teams
  
• Optimize extraction parameters using validated scientific inputs
  
• Reduce waste by minimizing trial-and-error and dialing in system performance
  
• Proactively guide strain-to-yield decisions with AI-powered analysis and literature-backed insights
  

Nabis Advances National Expansion Efforts With Blackbird Acquisition, Entering Nevada’s Wholesale Cannabis Market
Nabis Newsroom February 27, 2024

Nevada Operators Gain Access to Nabis’ Expanding Ecosystem and Streamlined Cannabis E-Commerce Platform, Facilitating Opportunities for Brands in a New Key Region

LAS VEGAS--(BUSINESS WIRE)--Nabis, the nation’s leading licensed cannabis wholesale platform, today announces its acquisition of Blackbird, the premier Nevada-based distribution solution. This transition will bring Nabis’ robust technology, infrastructure and exclusive brands to Blackbird’s unparalleled network of Nevada operators and retailers, further strengthening and streamlining efficiencies for operating partners throughout the state’s greater supply chain.

“Blackbird has done an incredible job of supporting Nevada’s strategically important cannabis market for brand building since the state’s legalization in 2016, and we’re honored to continue marching towards our shared vision alongside their team,” said Vince C. Ning, Co-CEO and Co-Founder of Nabis. “As we focus on serving customers nationwide through our platform, we’re looking forward to expanding Blackbird’s resources for customers in Nevada and continuing to foster the strong company culture the team has built.”

Combining Nabis’ leading marketplace and multi-channel fulfillment network with Blackbird’s established expertise in Nevada, this acquisition brings forth a new unified customer experience for cannabis wholesaling in the region. Nabis is now positioned as a centralized software platform for brands and retailers to efficiently conduct commerce, pioneering a one-stop-shop model to address the fragmented wholesaling options that currently exist in the US cannabis industry.

“This strategic partnership brings a powerful synergy to Nevada. It’s a bold step toward a brighter future for our cannabis partners statewide,” said Drea Ballard, Director of Operations at Blackbird. “Nabis shares our commitment of bringing excellence and efficiency to the cannabis supply chain, and we will be working closely with them to elevate our combined strengths.”

Blackbird’s operations and infrastructure currently services approximately 25% of Nevada’s cannabis market, and is a trusted partner for a multitude of reputable brands, operators, and MSOs. Through Nabis’ acquisition, brands will now benefit from a greater investment of resources from the industry’s leading platform. Nabis will bolster existing operations with a dynamic suite of tech tools including comprehensive sales insights and unparalleled payment solutions.

As the top licensed cannabis wholesaling platform, Nabis' acquisition of Blackbird not only strengthens the multi-state supply chain, but also offers operating partners a clear path toward regional expansion into Nevada’s burgeoning market. This opportunity is a pioneering roadmap to capitalize on the connection between two of the country’s most vital cannabis markets: California, the largest legal market in the US, and Nevada, which is ranked 3rd for most visited state in the country with nearly 40 million people visiting the state on an annual basis.

“Blackbird is already an incredibly well-respected player in Nevada's market,” said Ning. “And as Nabis sets its sights on national and potentially international horizons, we’re excited about the combined strengths of this acquisition leading the industry toward a new era of cannabis commerce.”

Learn more about Nabis’ wholesale platform at nabis.com.

‍About Nabis

Nabis is the #1 licensed cannabis wholesale platform, servicing over 300 brands. Founded in 2018 by serial tech entrepreneurs Vince C. Ning and Jun S. Lee, Nabis is on a mission to build the most powerful licensed cannabis wholesale platform with a multi-channel fulfillment network that simplifies cannabis commerce for brands and retailers anywhere in the world. Nabis is the largest licensed wholesaler in the industry, having supported numerous exclusive brands and retailers transact over $1B worth of cannabis products in major states across the nation. As Nabis continues its national expansion, the privately-held multistate operator utilizes its experience in the world’s largest legal cannabis markets and offers its partners an online wholesale marketplace with best-in-class fulfillment, payment processing, financing, data analytics, and sales and marketing services to enable more brands and retailers to innovate, launch, and scale strategically. Ning and Lee’s work earned Nabis a spot on Inc. 5000’s list of Fastest Growing Private Companies in America in 2023. Learn more: nabis.com

https://www.businesswire.com/news/home/2...7423232/en

Mike Tyson Sues Former Cannabis Business Partners For $50M
Tyson and wrestling legend Ric Flair are suing ex Carma execs for damages, attorneys' fees, and other associated costs.



Two legendary sports figures, boxing’s Mike Tyson and wrestling’s Ric Flair, have filed a lawsuit against former executives and a shareholder of Carma, alleging fraud, breach of contract, and other claims related to cannabis businesses that use their likenesses.

According to Front Office Sports, the lawsuit was filed in U.S. District Court in Illinois By Tyson, Flair, Carma, and LGNDS alleging that Chad Bronstein, Adam Wilks, Nicole Cosby, and James Case were involved in a “brazen RICO conspiracy involving criminal wire fraud, embezzlement, money laundering, and extortion, as well as securities fraud and shameless self-dealing that enriched the Defendants to the tune of tens of millions of dollars.”

The plaintiffs request a jury trial and more than $50 million in damages, attorneys’ fees, and other associated costs.

Bronstein was formerly Carma’s president and chairman; Wilks was the company’s CEO; and Cosby served as the chief legal and licensing officer. Case is a shareholder in the company. The cannabis products named after Tyson (Tyson 2.0) and Flair (Ric Flair Drip) were distributed by Carma and LGNDS.

The lawsuit states, “Throughout their time at CARMA, Bronstein and Wilks treated CARMA as their own personal piggy bank, using more than $1 million to pay for unauthorized personal travel on private jets, costs associated with Bronstein’s personal yacht, renovations to Bronstein’s personal residence, a mortgage payment for Wilks’ personal residence, and lavish entertainment expenditures for Wilks, including exorbitantly priced meals and travel expenditures, as well as excessive and unapproved compensation and bonuses.”

The former executives have been accused of selling licensing rights they were not authorized to sell under agreements with the athletes. Wilks allegedly had an undisclosed “kickback” deal with vape maker DomPen, where he received “concealed payments in exchange for turning a blind eye to DomPen’s unauthorized use of CARMA’s intellectual property.”

The defendants deny the accusations and accuse the plaintiffs of trying to intimidate them in what they refer to as a “shakedown.”

“The complaint is fiction dressed up as a lawsuit,” Jonathan Cyrluk, the attorney for Bronstein and Cosby, told the media outlet in a written statement. “Before filing, the plaintiffs tried to intimidate my clients with settlement demands that read more like a shakedown than a legal claim—demanding millions of dollars and attempting to force others to surrender their Carma shares.”

“My clients won’t be bullied and are prepared to knock out this meritless lawsuit in court.”

blackenterprise.com/mike-tyson-ric-flair-sue-cannabis-partner/

Federal: Lawmakers Approve Funding Bill Restricting Sales of Certain Hemp-Derived Intoxicating Products
by NORML Posted on November 13, 2025

Washington, DC: Federal lawmakers have negotiated and finalized legislation to fund the US Department of Agriculture that includes amended provisions recriminalizing the sale of certain hemp-derived intoxicating products. The appropriations bill is one of three separate funding bills that were included in a package to reopen the government until January 30, 2026.

The provisions – which were advocated by Sen. Mitch McConnell (R-KY), among others – target products containing delta-8 THC and similar compounds, as well as products that are synthetically derived from hemp. Specifically, the bill redefines federally legal hemp products as only those containing no more than either 0.3 percent or 0.4 milligrams of THC or other cannabinoids that produce similar effects, including THCA. In addition, it criminalizes “any intermediate hemp-derived cannabinoid products which are marketed or sold as a final product or directly to an end consumer for personal or household use” as well as products that are produced following chemical synthesis, such as those high in delta-8 THC content.

Although delta-8 THC occurs organically in the cannabis plant, it is typically only produced in nominal quantities. By contrast, the elevated amounts of delta-8 THC present in commercially available products are typically the result of a chemical synthesis during which manufacturers convert hemp-derived CBD to delta-8 THC.

While the revised language is not explicitly intended to target hemp-derived CBD products marketed as non-intoxicating products, some industry advocates fear that these products will also ultimately be banned by the legislation because many of them contain trace levels of THC.

An effort by Sen. Rand Paul (R-KY) to strike the amended language failed on the Senate floor, as did a similar effort in the House by Rep. Tom Massie (R-KY). A spokesperson for the White House previously acknowledged that President Trump “supports” the revisions to the 2018 hemp law, despite the President having signed the bill into law seven years ago.

The revised federal language will take effect in one year after its passage.

Nearly half of all US states already impose severe restrictions on the retail sale of delta-8 THC and similar products and federal courts have repeatedly upheld these bans.

NORML has consistently urged the FDA to establish regulatory guidelines governing the production, testing, labeling, and marketing of hemp-derived intoxicating cannabinoid products, but has argued against recriminalizing them.

“Federally recriminalizing the hemp-derived marketplace will neither reduce consumers’ demand for these products nor increase consumers’ safety,” NORML’s Deputy Director Paul Armentano said.

https://norml.org/news/2025/11/13/federa...-products/

2025 Year in Review: NORML’s Top Ten Events in Marijuana Policy
by NORML Posted on December 30, 2025

#1: President Trump Takes Executive Action to Federally Reschedule Cannabis

President Donald Trump issued an executive order in December directing the US Attorney General to finalize a Biden-era recommendation to amend marijuana’s longstanding classification as a Schedule I federally controlled substance. Prior to signing the order, Trump said, “These facts compel the federal government to recognize that marijuana can be legitimate in terms of medical applications.”

Commenting on the order, NORML’s Deputy Director Paul Armentano said, “While such a move potentially provides some benefits to patients, and veterans especially, it still falls well short of the changes necessary to bring federal marijuana policy into the 21st century.”

Despite the Administration’s action, it remains unclear when a change in marijuana’s federal scheduling will be codified. Any final order to reclassify cannabis is subject to a period of judicial review, whereby interested parties have an opportunity to challenge the order, which could further delay its implementation.

#2: GOP Lawmakers Undermine Voter-Approved Marijuana Measures

Republican lawmakers in various states took actions this year amending or repealing voter-approved marijuana laws.

In Texas, Republican Attorney General Ken Paxton sued several cities, including Austin and San Marcos, to overturn voter-initiated marijuana depenalization laws. In Nebraska, lawmakers and regulators gutted the state’s voter-approved medical cannabis access law by rescinding patients’ access to botanical cannabis, among other restrictions. In Ohio, Republican lawmakers approved legislation rolling back legal protections for adult-use cannabis consumers and recriminalizing various marijuana-related activities, including obtaining cannabis products from out-of-state retailers.

In response to this trend, NORML’s Deputy Director Paul Armentano said: “In a healthy democracy, those with competing visions on public policy vie for voters’ support and abide by their voting decisions. However, it is becoming clear that those who oppose marijuana policy reform would rather take voters out of the equation altogether. Whether or not one personally supports or opposes cannabis legalization, these undemocratic tactics ought to cause deep concern.”

#3 Federal Data: Teen Marijuana Use Continues Historic Decline

Federally funded survey data compiled by the University of Michigan in December reports that teens’ use of marijuana has declined significantly since states began regulating adult-use cannabis markets, and it now stands at or near historic lows.

Between 2012 and 2025, the percentage of 12th graders reporting having ever used cannabis fell by 23 percent. Among 10th graders, it fell 35 percent. Among 8th graders, lifetime use dropped 17 percent. During that same time period, past-year cannabis use fell 30 percent among 12th graders, 44 percent among 10th graders, and 34 percent among 8th graders. The percentage of teens reporting having consumed cannabis over the past 30 days also declined significantly — falling 25 percent among 12th graders, 45 percent among 10th graders, and 38 percent among 8th graders.

“We are encouraged that adolescent drug use remains relatively low and that so many teens choose not to use drugs at all,” said Dr. Nora D. Volkow, Director of NIH’s National Institute on Drug Abuse (NIDA), in a press release.

#4: Congress Approves Legislation Restricting Sales of Hemp-Derived Intoxicants

Federal lawmakers in November finalized and passed legislation recriminalizing the sale of certain hemp-derived intoxicating products. The law – which doesn’t take effect until November 2026 – redefines federally legal hemp products only to include those containing no more than either 0.3 percent or 0.4 milligrams of THC or other cannabinoids that produce similar effects, including THCA. In addition, it criminalizes “any intermediate hemp-derived cannabinoid products which are marketed or sold as a final product or directly to an end consumer for personal or household use” as well as products that are produced following chemical synthesis, such as those high in delta-8 THC content.

While the revised language is not explicitly intended to target hemp-derived, non-intoxicating CBD products, some industry advocates fear that these products will also ultimately be banned by the legislation because they often contain trace levels of THC. However, in December, President Trump called on his aides to work with Congress to ensure that patients do not lose access to regulated CBD products.

#5: Marijuana Arrests Continue to Decline

State and local law enforcement made nearly 190,000 marijuana possession-related arrests in 2024, according to data compiled by the US Federal Bureau of Investigation and posted on its Crime Data Explorer website. While that total represents a 30-year low, marijuana-related arrests still comprise more than 22 percent of all drug arrests nationwide. In five states (Idaho, Iowa, Louisiana, Nebraska, and Wisconsin), more than half of all drug-related arrests reported by state and local law enforcement agencies in 2024 were cannabis-related.

Marijuana arrests peaked in the United States in 2007, when police made over 870,000 marijuana-related arrests. At that time, just under half (48 percent) of all drug-related arrests in the United States were for marijuana-related violations.

#6: Longitudinal Trials Show Cannabis Provides Sustained Benefits for Patients

Chronically ill patients experience sustained symptomatic relief from either herbal cannabis or oil extracts, according to the findings of numerous longitudinal trials published in 2025.

According to the results of the trials, which included thousands of patients, cannabis preparations were safe and effective for periods of up to 18 months for those suffering from pain, insomnia, fibromyalgia, treatment-resistant epilepsy, post-traumatic stress, hypermobility disorders, endometriosis, and numerous other conditions.

Most of the participants in the trials are enrolled in the UK Medical Cannabis Registry. Under British law, health care providers may prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.

#7 November Election Outcomes Could Reshape East Coast Cannabis Markets

The election of Democratic Governors in New Jersey and Virginia could lead to the expansion of those states’ adult-use cannabis policies in 2026.

In Virginia, Abigail Spanberger will replace Republican Gov. Glenn Youngkin, who on multiple occasions vetoed legislation regulating the retail sale of cannabis products to adults. By contrast, Governor-elect Spanberger has pledged, “I look forward to working with our General Assembly to find a path forward to creating a legalized retail market for cannabis that both prioritizes public safety and grows Virginia’s economy.”

In New Jersey, Governor-elect Mikie Sherrill supports expanding New Jersey’s adult-use cannabis program, including allowing home cultivation and improving consumer access, safety, and affordability.

#8: Studies Consistently Show Cannabis Access Reduces Alcohol Consumption

Several studies published in 2025 report that consumers significantly reduce their alcohol intake following the use of cannabis.

In one study, subjects in a laboratory setting reduced their intake of alcoholic beverages by 25 percent following cannabis inhalation. In another study, participants reduced their alcohol intake by as much as 27 percent following cannabis consumption.

Finally, in a third study, patients seeking treatment for alcohol use disorder “consumed a mean of 8.08 daily MAP [Managed Alcohol Program]-provided standard drinks prior to the introduction of cannabis substitution and a mean of 6.45 daily MAP-provided standard drinks after its introduction.”

Commenting on the consistent results, NORML’s Deputy Director Paul Armentano said: “These findings provide support for the idea that legal cannabis can serve as a substitute for alcohol among certain individuals, and that legal cannabis markets may, in some instances, disrupt alcohol-dominant marketplaces.”

#9: Marijuana Legalization Support Remains High, But Dips Among Republicans

Nearly two out of three US adults say that “the use of marijuana should be legal,” according to nationwide polling data compiled in November by Gallup. That percentage represents a slight dip from 2024 data, when 68 percent of respondents backed legalization.

The percentage change was primarily driven by declining support among Republicans – only 40 percent of whom endorse marijuana legalization. By contrast, 85 percent of Democrats support legalization – a near all-time high, as do 66 percent of Independents.

Historically, Republicans have been less likely than either Democrats or Independents to express support for legalization. In 2023, 55 percent of Republicans endorsed legalizing marijuana, the highest percentage ever.

#10: NIH Database Now Includes Over 53,000 Cannabis-Related Studies

For the fifth consecutive year, researchers worldwide published over 4,000 scientific papers specific to cannabis, its active constituents, and their effects, according to the results of a keyword search of the National Library of Medicine/PubMed.gov website.

“Despite the perception that marijuana has yet to be subject to adequate scientific scrutiny, scientists’ interest in studying cannabis has increased exponentially in the past decade, as has our understanding of the plant, its active constituents, their mechanisms of action, and their effects on both the user and upon society,” NORML’s Deputy Director Paul Armentano said. “It is time for politicians and others to stop assessing cannabis through the lens of ‘what we don’t know’ and instead start engaging in evidence-based discussions about marijuana and marijuana reform policies that are indicative of all that we do know.”

Over the past decade, there has been a dramatic increase in scientific inquiries about the cannabis plant — with researchers publishing more than 37,000 scientific papers about cannabis since the beginning of 2015. As of this writing, PubMed.gov cites over 53,000 scientific papers on marijuana dating back to the year 1840.

https://norml.org/news/2025/12/30/2025-y...na-policy/

Ohio: Governor Signs Legislation Undermining Voter-Approved Adult-Use Marijuana Legalization Law
by NORML Posted on December 22, 2025

Republican Gov. Mike DeWine on Friday signed legislation (SB 56) into law amending and repealing key provisions of the state’s voter-approved adult-use legalization law.

The Republican-spearheaded bill make numerous changes to Ohio’s hemp and marijuana laws. Among the more significant changes, it criminalizes possessing marijuana products obtained from out-of-state, including products legally purchased at licensed dispensaries in neighboring jurisdictions. No other legalization state imposes such restrictions.

It also repeals provisions protecting adult-use consumers from facing either workplace or professional disciplinary action, as well as other forms of discrimination based solely upon their private marijuana use (such as the denial of parental rights or certain hospital procedures, such as organ transplants). It imposes new arbitrary limits on the percentages of THC permitted in adult-use and medical cannabis concentrates and it caps the total number of retail licenses permitted statewide. It also imposes new criminal sanctions upon those who either possess or transport certain cannabis products if they are not in their original, unopened packaging, among other restrictions.

Other provisions in the bill restrict the the retail sale of hemp-derived products, including beverages, solely to state-licensed dispensaries. That restriction will take effect in 90 days. Although lawmakers included language in the bill delaying the beverage ban for one year, the Governor vetoed that explicit provision.

NORML lobbied against lawmakers’ efforts to roll back the law, which was approved in 2023 by 57 percent of voters. In an op-ed in The Columbus Dispatch, NORML’s Deputy Director Paul Armentano and Political Director Morgan Fox said: “Legislators do not have the right to play Monday morning quarterback simply because most Ohioans voted in a way they disapprove.” NORML’s action alert opposing SB 56 was shared with lawmakers over 24,000 times. It states: “This bill is a slap in the face to the millions of Ohioans who voted in favor of Issue 2. Once again, politicians are arrogantly trying to claim that the public didn’t know what they were voting for.”

NORML’s Deputy Director Paul Armentano said that the GOP-led actions in Ohio are part of a growing and disturbing nationwide trend. In recent years, lawmakers in Republican-led states have become increasingly hostile to voter-approved marijuana laws, despite their bipartisan public support. For instance, lawmakers in Mississippi and South Dakota successfully sued to nullify election results in those states legalizing cannabis. In Texas, Republican Attorney General Ken Paxton sued several cities to overturn voter-initiated marijuana depenalization laws. In Nebraska, lawmakers and regulators have largely gutted the state’s voter-approved medical cannabis access law.

“In a healthy democracy, those with competing visions on public policy vie for voters’ support and abide by their voting decisions. However, it is becoming clear that those who oppose marijuana policy reform would rather take voters out of the equation altogether,” Armentano said. “Whether or not one personally supports or opposes cannabis legalization, these undemocratic tactics ought to cause deep concern.”

Read the enrolled text of Senate Bill 56. A summary of SB 56’s revisions to Ohio’s adult-use marijuana legalization and hemp laws is available from Ohio State University.

https://norml.org/blog/2025/12/22/ohio-g...a-policy&&

Case Reports: Cannabis Oil Associated With Tumor Regression in Patients With Advanced Liver Cancer
by NORML Posted on December 11, 2025

Groningen, Netherlands: A pair of patients with advanced hepatocellular carcinoma (HCC) experienced spontaneous tumor regression following the daily use of cannabis extracts, according to data published in the Journal of Cannabis Research.

Dutch investigators documented “complete” tumor regression in a pair of patients with advanced HCC. Both patients consumed THC-dominant cannabis oils daily. Neither patient engaged in any significant lifestyle, dietary, or other supportive interventions aside from the use of cannabis extracts.

Spontaneous regression of HCC typically occurs in fewer than one-half of one percent of all cases.

The study’s authors concluded: “In this report, we present two patients (ages 82 and 77) with advanced HCC with a high tumor burden who demonstrated durable and complete regression after use of cannabis oil. … The observations in this report build on previous (pre)clinical research highlighting the potential anti-tumor qualities of cannabinoids and stress the need for clinical trials investigating the anti-tumor effects of cannabinoids in cancer patients.”

Cannabinoids have demonstrated well-established anti-cancer activities in preclinical models, but their efficacy as an anti-cancer agent has rarely been assessed in clinical trials.

Full text of the study, “Durable complete response of advanced hepatocellular carcinoma using cannabis oil: A report of two cases,” appears in the Journal of Cannabis Research.

https://norml.org/news/2025/12/11/case-r...er-cancer/